Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takemasa Tsuji

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Oncotarget|July 18, 2020
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancerTakemasa Tsuji, Kevin H Eng, Junko Matsuzaki, et al.
Cancer Immunology Research|July 1, 2024
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLsBowen Dong, Nataša Obermajer, Takemasa Tsuji, et al.
Cancer Immunology Research|February 19, 2014
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancerKunle Odunsi, Junko Matsuzaki, Smitha R James, et al.
Journal for Immunotherapy of Cancer|March 25, 2025
mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumorsHenry G Withers, Junko Matsuzaki, Mark Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patientsPaul Sabbatini, Takemasa Tsuji, Luis Ferran, et al.
Journal for Immunotherapy of Cancer|June 22, 2019
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancerSong Liu, Junko Matsuzaki, Lei Wei, et al.
Cancer Research Communications|October 23, 2023
Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in HumansAlexandra V Vylegzhanina, Ivan A Bespalov, Ksenia A Novototskaya-Vlasova, et al.
Cell Reports. Medicine|September 2, 2025
Zeaxanthin augments CD8<sup>+</sup> effector T cell function and immunotherapy efficacyFreya Q Zhang, Jiacheng Li, Rukang Zhang, et al.
Science Translational Medicine|March 16, 2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.
Nature|November 22, 2023
Trans-vaccenic acid reprograms CD8<sup>+</sup> T cells and anti-tumour immunityHao Fan, Siyuan Xia, Junhong Xiang, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Oncotarget|July 18, 2020
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancerTakemasa Tsuji, Kevin H Eng, Junko Matsuzaki, et al.
Cancer Immunology Research|July 1, 2024
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLsBowen Dong, Nataša Obermajer, Takemasa Tsuji, et al.
Cancer Immunology Research|February 19, 2014
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancerKunle Odunsi, Junko Matsuzaki, Smitha R James, et al.
Journal for Immunotherapy of Cancer|March 25, 2025
mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumorsHenry G Withers, Junko Matsuzaki, Mark Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patientsPaul Sabbatini, Takemasa Tsuji, Luis Ferran, et al.
Journal for Immunotherapy of Cancer|June 22, 2019
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancerSong Liu, Junko Matsuzaki, Lei Wei, et al.
Cancer Research Communications|October 23, 2023
Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in HumansAlexandra V Vylegzhanina, Ivan A Bespalov, Ksenia A Novototskaya-Vlasova, et al.
Cell Reports. Medicine|September 2, 2025
Zeaxanthin augments CD8<sup>+</sup> effector T cell function and immunotherapy efficacyFreya Q Zhang, Jiacheng Li, Rukang Zhang, et al.
Science Translational Medicine|March 16, 2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.
Nature|November 22, 2023
Trans-vaccenic acid reprograms CD8<sup>+</sup> T cells and anti-tumour immunityHao Fan, Siyuan Xia, Junhong Xiang, et al.
Pageof 6